What Does Eisai Co., Ltd. Do?

Total employees11289
HeadquartersBunkyo-ku
Founded1941

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops, and markets pharmaceuticals worldwide. With a strong focus on neurology and oncology, Eisai is dedicated to addressing unmet medical needs and increasing the benefits for patients and their families. The company's hhc philosophy emphasizes understanding the perspectives of patients to develop innovative solutions.

Where Is Eisai Co., Ltd.'s Headquarters?

HQ Function

Serves as the global command center for strategic planning, research and development direction, corporate governance, financial management, and global administrative functions for Eisai's worldwide operations.

Notable Features:

Modern, purpose-built facilities integrating advanced research laboratories and corporate offices. The design likely reflects Japanese efficiency and a commitment to sustainability and innovation.

Work Culture:

Deeply rooted in its 'human health care' (hhc) philosophy, fostering a patient-centric environment. Emphasis on scientific rigor, ethical conduct, collaboration, and continuous learning. Influenced by Japanese corporate values of precision and long-term vision.

HQ Significance:

The Tokyo headquarters is pivotal for driving Eisai's global mission to make contributions to patients and society through the creation of innovative drugs in areas of high unmet medical needs, particularly neurology and oncology.

Values Reflected in HQ: The headquarters embodies Eisai's commitment to innovation, patient well-being, scientific excellence, global collaboration, and long-term societal contribution.

Location:

Eisai Co., Ltd. maintains a robust global presence with operations spanning Japan, the Americas, Europe, and Asia. The company supports worldwide functions including cutting-edge research and development, advanced pharmaceutical manufacturing, and comprehensive marketing and sales networks. This global footprint enables Eisai to deliver its innovative medicines and health care solutions to patients in numerous countries, addressing critical unmet medical needs on an international scale.

Street Address:

Koishikawa 4-6-10

City:

Bunkyo-ku

State/Province:

Tokyo

Country:

Japan

Where Else Does Eisai Co., Ltd. Operate Around the World?

Nutley, New Jersey/USA

Address: 200 Metro Boulevard, Nutley, NJ 07110, USA

Acts as the primary hub for Eisai's operations in the Americas, driving market access, product commercialization, and engagement with healthcare professionals and patient communities in the region.

Hatfield, Hertfordshire/United Kingdom

Address: Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, AL10 9SN, UK

Strategic center for Eisai's European operations, coordinating product launches, regulatory affairs, market development, and scientific collaborations throughout the EMEA region.

Buying Intent Signals for Eisai Co., Ltd.

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Eisai Co., Ltd.? Meet the Executive Team

As of April 2025, Eisai Co., Ltd.' leadership includes:

Haruo Naito - Representative Corporate Officer and CEO
Keisuke Naito - Representative Corporate Officer and COO
Ryohei Yanagi - Director, Senior Vice President, Chief Financial Officer (CFO)
Sayoko Sasaki - Director, Senior Vice President, Chief Governance Officer (CGO), Chief Compliance Officer (CCO)
Terushige Iwai - Senior Vice President, President, Oncology Business Group
Ivan Cheung - Senior Vice President, President, Neurology Business Group, Chairman and CEO, Eisai Inc.

Who's Investing in Eisai Co., Ltd.?

Eisai Co., Ltd. has been backed by several prominent investors over the years, including:

The Master Trust Bank of Japan, Ltd. (Trust Account)
Custody Bank of Japan, Ltd. (Trust Account)
Nippon Life Insurance Company
Meiji Yasuda Life Insurance Company
State Street Bank West Client - Treaty 505234

What Leadership Changes Has Eisai Co., Ltd. Seen Recently?

Hire1
Exits0

Eisai Co., Ltd. announced key leadership appointments and transitions in early 2023, aimed at strengthening its global operations and strategic focus, particularly with the appointment of a new COO.

New Appointments:

Keisuke Naito, Keisuke Naito assumed the role of Representative Corporate Officer and Chief Operating Officer (COO), taking on broader responsibilities for Eisai's global business operations.

What Technology (Tech Stack) Is Used byEisai Co., Ltd.?

Discover the tools Eisai Co., Ltd. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Eisai Co., Ltd. Email Formats and Examples

Eisai Co., Ltd. typically utilizes standardized email formats for its corporate communications. While multiple formats might exist, a common structure is often [first_initial][last] or [first].[last] @domain.com. For Eisai, the primary domain is eisai.com for global communications and eisai.co.jp for Japan.

[first].[last]@eisai.com or [first_initial][last]@eisai.com

Format

john.smith@eisai.com

Example

80%

Success rate

What's the Latest News About Eisai Co., Ltd.?

Eisai Co., Ltd. News ReleaseJanuary 9, 2024

Eisai's Alzheimer's Disease Treatment LEQEMBI® Approved in China

Eisai Co., Ltd. announced that LEQEMBI® Intravenous Infusion (lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, was approved by the National Medical Products Administration (NMPA) of China as a treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively known as early AD)....more

Eisai Co., Ltd. Investor RelationsFebruary 7, 2024

Eisai Announces Third Quarter FY2023 Financial Results and Progress on Key Products

Eisai reported its consolidated financial results for the third quarter of fiscal year 2023 (ended December 31, 2023). The company highlighted revenue growth driven by global products such as LEQEMBI and LENVIMA, and provided updates on its R&D pipeline, particularly in oncology and neurology, reaffirming its full-year guidance....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Eisai Co., Ltd., are just a search away.